Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2020 1
2021 1
2022 3
2023 5
2024 4
2025 3
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
An update on clinical trials for cutaneous lupus erythematosus.
Xie L, Lopes Almeida Gomes L, Stone CJ, Faden DF, Werth VP. Xie L, et al. J Dermatol. 2024 Jul;51(7):885-894. doi: 10.1111/1346-8138.17161. Epub 2024 Mar 15. J Dermatol. 2024. PMID: 38491743 Free PMC article. Review.
Cutaneous lupus erythematosus (CLE) comprises dermatologic manifestations that may occur independently or with systemic lupus erythematosus (SLE). ...To develop effective CLE treatments, validated outcome measures for tracking patient res …
Cutaneous lupus erythematosus (CLE) comprises dermatologic manifestations that may occur independently or with syste …
Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE.
Bao A, Petri MA, Fava A, Kang J. Bao A, et al. Lupus Sci Med. 2023 Dec 19;10(2):e001007. doi: 10.1136/lupus-2023-001007. Lupus Sci Med. 2023. PMID: 38114267 Free PMC article.
OBJECTIVE: To assess the efficacy of anifrolumab, a type-1 interferon receptor subunit-1 monoclonal antibody, in treating refractory cutaneous lupus erythematosus (CLE) and lupus non-specific mucocutaneous manifestations in patients with syst …
OBJECTIVE: To assess the efficacy of anifrolumab, a type-1 interferon receptor subunit-1 monoclonal antibody, in treating refractory …
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.
Furie RA, Morand EF, Bruce IN, Manzi S, Kalunian KC, Vital EM, Lawrence Ford T, Gupta R, Hiepe F, Santiago M, Brohawn PZ, Berglind A, Tummala R; TULIP-1 study investigators. Furie RA, et al. Lancet Rheumatol. 2019 Dec;1(4):e208-e219. doi: 10.1016/S2665-9913(19)30076-1. Epub 2019 Nov 11. Lancet Rheumatol. 2019. PMID: 38229377
BACKGROUND: Type I interferons are involved in systemic lupus erythematosus (SLE) pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1, suppressed interferon gene signatures and substantiall …
BACKGROUND: Type I interferons are involved in systemic lupus erythematosus (SLE) pathogenesis. In a phase 2 trial, …
Update on cutaneous lupus erythematosus pathogenesis, diagnosis and management.
Chasset F, Teboul A. Chasset F, et al. J Eur Acad Dermatol Venereol. 2026 May;40(5):782-800. doi: 10.1111/jdv.70186. Epub 2025 Dec 2. J Eur Acad Dermatol Venereol. 2026. PMID: 41328032 Review.
Cutaneous lupus erythematosus (CLE) encompasses a spectrum of skin manifestations that may occur as an isolated dermatological condition or in association with systemic lupus erythematosus (SLE). ...In recent years, validated tools such a …
Cutaneous lupus erythematosus (CLE) encompasses a spectrum of skin manifestations that may occur as an isolated dermato …
Anifrolumab for Nonsystemic Cutaneous Lupus Erythematosus: Clinical Experience, Immunologic Insights, and Review of the Literature.
Loricera J, Bejerano C, Estébanez A, García I, Mohammad N, Sanmartín M, González-Fernández M, Amaro IF, González-López MA, García-Contreras MV, López-Hoyos M, Blanco R. Loricera J, et al. J Clin Med. 2025 Aug 11;14(16):5683. doi: 10.3390/jcm14165683. J Clin Med. 2025. PMID: 40869510 Free PMC article.
Objective: Anifrolumab is approved for systemic lupus erythematosus (SLE). Its off-label use in non-systemic cutaneous lupus erythematosus (NSCLE) remains poorly characterized. ...Methods: This multicenter observational stud …
Objective: Anifrolumab is approved for systemic lupus erythematosus (SLE). Its off-label use in non-systemic …
Deucravacitinib shows superior efficacy and safety in cutaneous lupus erythematosus compared to various biologics and small molecules - A systematic review and meta-analysis.
Bokor LA, Martyin K, Krebs M, Galajda NÁ, Meznerics FA, Szabó B, Hegyi P, Lőrincz K, Kiss N, Bánvölgyi A, Hidvégi B. Bokor LA, et al. Autoimmun Rev. 2025 Feb 28;24(3):103723. doi: 10.1016/j.autrev.2024.103723. Epub 2024 Dec 16. Autoimmun Rev. 2025. PMID: 39694128 Free article.
BACKGROUND: Novel therapies for cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) demonstrated efficacy and safety in previous trials. ...The primary outcomes assessed were the proportion of patients achieving the …
BACKGROUND: Novel therapies for cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus …
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials.
Morand EF, Furie RA, Bruce IN, Vital EM, Dall'Era M, Maho E, Pineda L, Tummala R. Morand EF, et al. Lancet Rheumatol. 2022 Apr;4(4):e282-e292. doi: 10.1016/S2665-9913(21)00317-9. Epub 2022 Feb 3. Lancet Rheumatol. 2022. PMID: 38288923
BACKGROUND: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterised by multisystem involvement. ...We evaluated changes from baseline to week 52 in British Isles Lupus Assessment Group 2004 (BILAG-2004) and SLE Disease Activity …
BACKGROUND: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterised by multisystem involvement …
Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers.
Carter LM, Wigston Z, Laws P, Vital EM. Carter LM, et al. Br J Dermatol. 2023 Jul 17;189(2):210-218. doi: 10.1093/bjd/ljad089. Br J Dermatol. 2023. PMID: 36944572 Free article.
BACKGROUND: Observations with rituximab suggest B-cell independent mechanisms of cutaneous lupus erythematosus (CLE) in systemic lupus erythematosus (SLE), especially discoid lupus erythematosus (DLE). Type-I interferon rece …
BACKGROUND: Observations with rituximab suggest B-cell independent mechanisms of cutaneous lupus erythematosus (CLE) in …
Anifrolumab for systemic lupus erythematosus: A clinical study of Japanese patients in Kanazawa University Hospital.
Fushida N, Horii M, Oishi K, Matsushita T. Fushida N, et al. J Dermatol. 2024 Apr;51(4):607-611. doi: 10.1111/1346-8138.17027. Epub 2023 Nov 6. J Dermatol. 2024. PMID: 37929294
We investigated the effectiveness of anifrolumab in treating systemic lupus erythematosus (SLE). We treated seven patients with SLE (age range, 31-68 years; median age, 48 years); one male and six females) with anifrolumab between January 2022 a …
We investigated the effectiveness of anifrolumab in treating systemic lupus erythematosus (SLE). We treated seve …
Anifrolumab for systemic lupus erythematosus with multi-refractory skin disease: A case series of 18 patients.
Flouda S, Emmanouilidou E, Karamanakos A, Koumaki D, Katsifis-Nezis D, Repa A, Bertsias G, Boumpas D, Fanouriakis A. Flouda S, et al. Lupus. 2024 Oct;33(11):1248-1253. doi: 10.1177/09612033241273023. Epub 2024 Aug 4. Lupus. 2024. PMID: 39098049
OBJECTIVE: Skin involvement is common in systemic lupus erythematosus (SLE), but may be resistant to conventional treatment. We sought to evaluate the efficacy of anifrolumab (ANI) in refractory cutaneous manifestations of SLE. METHODS: Case ser …
OBJECTIVE: Skin involvement is common in systemic lupus erythematosus (SLE), but may be resistant to conventional treat …
20 results